Postpartum Depression

Research Update

Oral Zuranolone for Postpartum Depression

Topics: Depression | Postpartum Depression | Randomized controlled trial | steroids | Women’s Issues in Psychiatry

REVIEW OF: Deligiannidis KM et al, JAMA Psychiatry 2021;78(9):951–959 STUDY TYPE: Randomized controlled trial DSM-5 defines postpartum depression (PPD) as any major depressive episode that begins during pregnancy or within four weeks after giving birth. Traditional antidepressants have long been used during this period, but only small studies suppor

Read More
News of Note

Brexanolone (Zulresso) for Postpartum Depression

Topics: Depression | Depressive Disorder | Pharmacology | Postpartum Depression | Pregnancy

On March 19, 2019, the FDA approved brexanolone (Zulresso), the first medication for postpartum depression (PPD). Delivered by intravenous injection, brexanolone is an analogue of the hormone allopregnanolone. Allopregnanolone levels fall abruptly after childbirth, which is thought to contribute to PPD by destabilizing GABAA receptors. We covered brexa

Read More